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Normal cell-cycle progression is a crucial task for every multicellular organ-
ism, as it determines body size and shape, tissue renewal and senescence,
and is also crucial for reproduction. On the other hand, dysregulation of
the cell-cycle progression leading to uncontrolled cell proliferation is the
hallmark of cancer. Therefore, it is not surprising that it is a tightly regulated
process, with multifaceted and very complex control mechanisms. It is now
well established that one of those mechanisms relies on ion channels, and in
many cases specifically on potassium channels. Here, we summarize the
possible mechanisms underlying the importance of potassium channels in
cell-cycle control and briefly review some of the identified channels that
illustrate the multiple ways in which this group of proteins can influence
cell proliferation and modulate cell-cycle progression.
1. Introduction
Regulation of cell division is of great relevance for eukaryotes. Cells must pro-
liferate throughout ontogenesis, tissue renewal and remodelling, and to repair
damaged areas during wound healing. Defective cell-cycle checkpoints are a
common feature of cancer cells and the inactivation of cell cycle regulators deci-
des the physiological or pathological fate of stem cells. Although there are a
large number of studies on the molecular and biochemical mechanisms control-
ling the cell cycle, the bioelectrical modulation of cell-cycle progression is still
poorly understood. Kþ channels have been implicated in the control of cell-
cycle progression both through their influence on the membrane potential
and non-canonical, permeation-independent mechanisms.2. Checkpoints and transmembrane potential regulate
cell-cycle progression
The process that produces two daughter cells from a mother cell has been divi-
ded into several phases, each with very characteristic functional properties. Cell
division in eukaryotes starts with the G1 (gap 1) phase, which separates the
previous cell division from the period of DNA synthesis (S-phase), where
chromosome replication is accomplished. This is followed by the second gap
(G2) and the mitotic (M) phase. After M phase, a cell can proceed to a new G1
phase or enter a quiescent state (termed G0) that can last for a very long time,
even for the rest of the life of the cell in the case of end-differentiated cells. The
correct progression of the cycle is guaranteed because the initiation of a late
event is strictly dependent on the successful completion of the preceding step.
In eukaryotic cells, for example, mitosis will not start until the completion of
DNA synthesis. The interdependency of events is owing to a series of surveillance
or control mechanisms termed checkpoints, which have evolved to minimize the
production and propagation of genetic inaccuracies [1,2]. The complexmachinery
of cell-cycle checkpoints includes in all cases a sensor supervising the complete-
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Figure 1. Complete block of DNA synthesis, measures as [3H]thymidine incorporation in cells with fixed hyperpolarized membrane potential. Reproduced from [7]





 on February 10, 2014rstb.royalsocietypublishing.orgDownloaded from event, whichwill be a process involved in the actual replication
and segregation of the DNA. For instance, the downstream
event at the onset of S phase is DNA synthesis, the downstream
event at the onset of mitosis is the assembly of the spindle and
the downstream event at the end of mitosis is chromo-
some segregation [3,4]. Thus, checkpoints are constitutive
feedback control pathways safeguarding key cell-cycle tran-
sitions G1/S, G2/M and exit from mitosis [5]. The key
components of the mechanisms coordinating the downstream
events are cyclin/cyclin-dependent kinase (CDK) comp-
lexes, which need to be expressed in a timely fashion and/or
activated to allow cell-cycle progression.
The transmembrane potential has been reported as a cellu-
lar bioelectric parameter that influences the progression
through the cell cycle [6]. The concept came from the early
experimental observation of a correlation between the resting
membrane potential and the degree of mitotic activity [7];
forcing the membrane potential of Chinese hamster ovary
cells to a fixed hyperpolarized value completely inhibited
DNA synthesis measured as [3H]thymidine incorporation,
while cycling was recovered upon release of the potential
(figure 1). Cell types with a very hyperpolarized resting poten-
tial, such asmuscle cells and neurons, typically show little or no
mitotic activity. Inversely, it was reported in the early 1970s that
ouabain-induced depolarization was followed by the initiation
of DNA synthesis and subsequent mitosis in chick spinal cord
neurons [8,9]. Moreover, it has been shown that the membrane
potential is not constant during progression through the
cell cycle [10,11]. For example, the distribution of membrane
potentials in cells from the breast cancer cell line MCF-7 is
multimodal. The frequency of events at each maximum can
be shifted when experimental treatments change the distri-
bution of cells among the different phases of the cell cycle.
The results of these experiments showed a pattern of positive
correlation where the membrane potential hyperpolarizes
during the G1/S transition, there is a significant contribution
of depolarized cells towards G0/G1 and an enrichment in
hyperpolarized cells towards G2/M transition [12].3. Kþ channels as important players in the
cell cycle
If the membrane potential is not constant along the cell cycle,
cell-cycle-dependent changes in membrane permeability are
required (figure 2). Potassium conductance governs the resting
membrane potential in both excitable and non-excitable cells.In contrast to an action potential fired bya neuron, the potential
changes along the cell cycle are much slower, gradual and
smaller, and can be intuitively explained by modifications
in the conductance that sets the resting membrane potential.
Proliferationwas one of the first identified aspects of cell physi-
ology where potassium channels play a crucial role. The early
observation that wide-spectrum potassium channel blockers
inhibit proliferation [13] has been repeatedly confirmed in
many tissues and cell types (reviewed e.g. in [6]). Many differ-
ent potassium channels show cell-cycle-dependent variations
of expression or activity [14–17].
For instance, a large conductance, voltage-gated Kþ chan-
nel is expressed in unfertilized mouse oocytes; in the first cell
cycle of fertilized oocytes, the channel is active throughout M
and G1 phases, and inactive during S and G2. Thus, changes
in channel activity set the membrane potential along the cell
cycle in the oocyte [18]. Increasing evidence shows that vol-
tage-gated potassium channels are required for proliferation
and may also help to determine the final identity and mor-
phology of the cell [19–22]. The results of experiments in
lymphocytes where the inhibition of Kþ channel activity
induces a reversible cell-cycle arrest [23,24] or experiments
where potassium channel blockers inhibit Schwann cell pro-
liferation in a dose-dependent manner [22,25,26] have been
replicated in many systems and by many approaches; data
from those experiments have been compiled already in
several reviews (e.g. [27–31]).
Direct evidence for a change in ion channel composition
in G1 phase was obtained from embryonic retinal cells,
which express mainly two membrane conductances, delayed
rectifier (IK) and inward rectifier (IKir) potassium currents
[32]. Daughters of the same parental cell examined during
and after mitosis always expressed similar IK and IKir den-
sities. However, non-sibling cells showed quantitative and
qualitative differences in IK and IKir densities. The heterogen-
eity therefore arises after cells re-enter G1, because the density
distribution of potassium channels at cytokinesis is shown to
be symmetric in both daughter cells [33].
The mechanisms controlling ion channel densities along
the cell cycle appear to be manifold. For example, Kþ channel
activity in mouse oocytes is at least partly independent of the
nuclear cell-cycle clock, because channel activity continues
to cycle in bisected embryos in the anucleate as well as the
nucleate fragments [34]. This suggests the active contribution
of the cytoplasmic cell-cycle clock, which may involve changes
induced by surface contractions and deformations before the
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Figure 2. Schematic of the behaviour of the membrane potential along the cell cycle. Different potassium channels show variations of expression or activity through






 on February 10, 2014rstb.royalsocietypublishing.orgDownloaded from Thus, potassium channels are proposed to be involved in the
signal transduction elicited by cell-cycle checkpoints, and
help to elicit cell responses in the cell-cyclemachinery, integrat-
ing the nuclear clock and the cytoplasmic cell-cycle clock.
Pointing towards this hypothesis, there have been reports
where Kþ channel blockers (TEA) and depolarizing agents
(veratridine) inhibit cell proliferation in oligodendrocyte pro-
genitors in cell culture and cerebellar tissue slices, inducing
G1 arrest through accumulation of p27kip1 and p21CIP1, two
CDK inhibitors known to regulate cell proliferation [36,37].4. Importance of Kþ channels relies on both
ionic conduction and permeation-
independent mechanisms
The participation of Kþ channels in the control of cell cycle
could be an early event in evolution. The pore structure and
the selectivity filter have been conserved between the prokar-
yotic and eukaryotic Kþ channels [38], which suggests that
they evolved very early. The importance of Kþ channels in
the cell-cycle progression can also be illustrated in plant cells,
for which Kþ is a major nutrient. BY-2 tobacco cells require
an increase in the Kþ concentration in order to re-enter the
cell cycle. The elevated Kþ concentration increases the turgor
pressure, which is required for cell growth. This is achieved
by the activity of the inward rectifier Kþ uptake channels
[39]. By contrast, mitosis requires a transient decrease in
turgor pressure owing to Kþ efflux channels. In what could
be a reminiscence of this function, the role of Kþ channels in
homoeostatic cell volume regulation is well established, and
they play a role in cell volume changes along the cell cycle
[40,41]. For instance, in a subset of human medulloblastomas,
a voltage-gated Kþ channel (KV10.2) seems to be required for
the completion of mitosis, because it participates in cell
volume reduction prior to cytokinesis [21].
Kþ channels also provide the driving force required for
Ca2þ to enter the cell by shifting the membrane potential
towards negative values. Ca2þ is an important mediator of
intracellular signals implicated in the control of proliferation
among other crucial processes in cell physiology, and by keep-
ing the membrane potential at hyperpolarized values, Kþ
channels ensure efficient Ca2þ entry into the cell [42–45].Still, regardless of whether the potassium gradient is used to
generate driving force for Ca2þ or to change the cell volume,
we traditionally tend to define the potassium current as
the only effector, and ignore possible additional actions
of the ion channelmolecule itself. If only Kþ flowwas required,
essentially any potassium channel expressed at the right
moment would be able to affect cell-cycle progression. Exper-
imental observations using either siRNA knockdown or
specific blockers, for example antibodies, have repeatedly
shown, however, that a specific potassium channel can be
important for proliferation (e.g. [46–50]). This would indicate
a permeation-independent, non-canonical mechanism that
could involve protein–protein interactions, dependent or inde-
pendent of the conformational changes of the channel
mediated by voltage. Non-canonical functions [51] have been
described for at least the Drosophila eag channel [52], its mam-
malian orthologue KV10.1 [53], KV1.3 [54] and KCa3.1 [55],
which are still able influence cell proliferation in the absence
of Kþ permeation. Moreover, an alternatively spliced form of
Drosophila eag that lacks the transmembrane regions, and there-
fore is not even a bona fide potassium channel has also been
reported to influence intracellular signalling and alter cell
morphology in the background of PKA/PKC activation [56].
In more general terms, the fact that more than 70 genes
encode Kþ channels suggests an exquisite distribution of
functions among specific molecular entities, rather than a
homogeneous function for all potassium channels. Along
these lines, the variability of Kþ channels is further increased
by the formation of heteromultimers, the influence of accessory
subunits and a large number of post-translational modifi-
cations, such as glycosylation [57], phosphorylation [58] and
sumoylation [59]. There is substantial evidence that several
Kþ channels play a role in cell cycle and proliferation by
means of both permeation-related and unrelated mechanisms
(figure 3). Below, we describe some of them in more detail.5. KV1.3
KV1.3 (together with KCa3.1) was probably the first case
showing the involvement of Kþ channels in cell proliferation
[13,60]. In a very early report on T lymphocytes, mitogenesis
induced by phytohaemagglutinin caused Kþ channels to
































Figure 3. Kþ channels influence cell-cycle progression through permeation-related and non-canonical mechanisms. The former include cell volume regulation,
modulation of membrane potential and generation of driving for Ca2þ, while the latter rely on protein–protein interactions. Kþ channel expression or function
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esis [13]. KV1.3 blockade was shown to suppress T-cell
activation and Ca2þ signalling in human T cells owing to
membrane depolarization, resulting in a reduced driving
force for Ca2þ entry and impairment of activation by agents
inducing mitogenesis [61,62]. KV1.3 can act in conjunction
with KCa3.1, which is a Ca
2þ-dependent Kþ channel activated
by Ca2þ–calmodulin [63]. KV1.3 and KCa3.1 have been found
to cluster at the immunological synapse following contact
with an antigen-presenting cell [60]. Together, KV1.3 and
KCa3.1 modulate calcium-dependent cellular processes in
immune cells, such as T-cell activation and proliferation
[43,64]. KCa3.1 has also been implicated in the control of
cell proliferation in rat mesenchymal stem cells, vascular
smooth muscle cells (VSMCs), hepatocellular carcinoma
cells as well as endometrial and prostate cancer cells
[45,46,65–68], although in glioma cells KCa3.1 knockdown
abolished the current but did not affect proliferation [69].
As KCa3.1 seems to play a crucial role in glioma cell migration
[70–75], it might be difficult to dissect both properties and
the results can depend very strongly on the methods used
to determine proliferation.
KV1.3 has also been implicated in the control of the
cell cycle in many other cell types, such active microglia cells
[76,77], proliferating oligodendrocyte progenitors during
G1/S transition [37] and macrophages [78–80]. In human
endothelial cells, vascular endothelial growth factor induces
a KV1.3-dependent hyperpolarization that results in an
increased Ca2þ entry, which is responsible for the effects on
proliferation [81,82]. It has been shown that the contractile
activity of VSMCs controlling blood flow changes during the
course of several vascular disorders and the cells acquire a pro-
liferative and migratory phenotype [83]. KV1.3 functional
expression is associated with the proliferative phenotype,
because the blockade of the channel induces a significant
inhibition of cell proliferation [81,84,85]. Switching from con-
tractile to proliferative phenotype is thus associated with
changes in ion channel activity. However, one study suggestsKV1.3 increases VSMCproliferation by voltage-dependent con-
formational changes of the channel that activate intracellular
signalling pathways, rather than by ionic conduction [54].6. KV11.1
The voltage-sensitive human ether a` go-go-related gene
(hERG, KV11.1) [86] potassium channels have emerged as
regulators of both proliferation and survival in cancer cells.
KV11.1 (encoded by KCNH2) channel expression in normal
adult human tissue is abundant in heart, brain, myometrium,
pancreas and haematopoietic progenitors [87–90]. KV11.1
expression has been reported in many cancer types as well
as cancer cell lines of different lineages, be it epithelial, leuke-
mic, connective or neuronal [89–91] Various studies have
demonstrated this expression to be largely confined to neo-
plastic cells both in solid and haematological malignancies,
when compared with neighbouring normal tissues or
normal bone marrow samples [90–94]. Studies over the
past decade have also shown its expression to be preferential
to the cancer stem cells especially in leukaemia when com-
pared with normal haematopoietic stem cells [90,94].
KV11.1 expression has also been linked to higher grade and
worse prognosis, both in the case of solid as well as haema-
tological malignancies [89,91–94]. KV11.1 expression is not
an epiphenomenon of cancer cells and rather plays a relevant
role in their proliferative capacity, for both haematological as
well as solid tumours [49,90–98]. Studies by various groups
on KV11.1 inhibition in cell lines derived from solid tumours
or leukaemias have shown a clear reduction in proliferation
[49,90–99]. The reduction in cell proliferation has been
explained by either increase in apoptosis or an arrest at the
G0/G1 phase of cell cycle [49,90–99]. Nevertheless, the
anti-tumour effects of blockers of KV11.1 appear to act
through a reduction in cell proliferation [49,82,98,99]. Some
studies have implicated the two isoforms of hERG (hERG1a
and hERG1b) to play a vital role not only in cell proliferation
rstb.royalsocietypublishing.org
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nel kinetics and current amplitude [100]. Both isoforms have
been shown to coexist, but hERG1b expression is more pro-
minent in the S phase of the cell cycle and hERG1a
expression in the G1 phase. Modulation of these expression
patterns affects the cell proliferation [95]. Co-assembly of
hERG1awith hERG1b results in increased availability of chan-
nels on the plasma membrane and a larger current flow when
compared with homomeric forms of the channel [100]. Further
insight into the hERG isoforms and its role in cancer is needed
to conclusively designate hERG as a therapeutic target.Phil.Trans.R.Soc.B
369:201300947. KV10.1
KV10.1 (Eag1, encoded by KCNH1) is one of the best-studied
ion channels in the context of cancer. Its oncogenic poten-
tial was first described in 1999 with the discovery that the
inhibition of KV10.1 expression reduces proliferation of sev-
eral somatic cancer cell lines [101]. KV10.1 overexpression,
in turn, increases cell proliferation and can confer a trans-
formed phenotype. In the same study, our laboratory also
reported that KV10.1 is undetectable in healthy tissues out-
side the brain and favours xenograft tumour progression in
immunodeficient mice in vivo. Along these lines, KV10.1 has
also been detected in approximately 70% of human tumour
biopsies of diverse origin [102–113]. Its widespread presence
in clinical samples, together with the fact that the physiologi-
cal expression of KV10.1 is confined to the brain (with the
exception of a few restricted cell populations [111]), aroused
a lot of interest in the channel owing to its potential thera-
peutic and diagnostic applications. It had been assumed
that KV10.1 is present only in solid tumours but recent
research has revealed its presence in leukaemias, correlating
with a poor prognosis [107]. KV10.1 expression also correlates
with poor prognosis for patients of ovarian [106], gastric
[112] and colon cancer [114], and with lymph node meta-
stasis in gastric cancer and head and neck squamous cell
carcinoma, where it also correlates with the disease stage
[105].Moreover, a number of studies have supported the obser-
vation that KV10.1 blockage or knockdown decreases the
proliferation of many cancer cell lines and in vivo tumour
models [53,107,115,116]. An interesting exception here is glio-
blastoma, where the levels of KV10.1 are lower than that in
healthy brain tissue [109], while further silencing of channel
expression increases the responsiveness to interferon gamma
treatment [117]. Although it is probably not the only relevant
localization of KV10.1 [118], it is also worth mentioning here
that membrane localization makes KV10.1 an attractive target
for therapy, as it is easily accessible from the extracellular
side. In order to selectively induce apoptosis in cancer cells,
an anti- KV10.1 antibody has been coupled to TNF-related
apoptosis-inducing ligand, and this strategy has been
successfully tested in vitro [119].
The mechanisms of how KV10.1 is able to increase cell
proliferation and favour tumour progression remain elusive.
Ion permeation does not seem to be a necessary condition
for either of the above, as non-conducting mutants retain
the ability to influence proliferation and tumourigenesis
[52,53]. By implication, the advantage KV10.1 expression con-
fers is independent of the ‘classical’ contributions of Kþ
channels to proliferation: regulating cell volume, maintaining
the driving force for Ca2þ and G1/S hyperpolarization. Aswe already indicated earlier, this is less surprising than it
may appear, because if the features associated with Kþ per-
meation were enough to render a transformed phenotype,
many more Kþ channels would be oncogenic. Moreover,
the loss of ionic conductances can often be compensated
for by other channels, which also does not fit into the pic-
ture where removing a particular conductance drastically
reduces proliferation in so many cancer cell lines, as well as
tumourigenesis in vivo. In contrast to ion permeation, vol-
tage-dependent conformations may be crucial for KV10.1 to
support proliferation, as the non-conducting mutants that
have a preference for the open conformation fail to influence
proliferation [52]. It is important to note that channel blockers
could reduce proliferation not only by inhibiting permeation,
but also by trapping the channel in a particular conformation.
Hegle and co-workers also described an increase in p38-MAP
kinase activity in non-cancer cells transfected with KV10.1,
and abolishing the effect of KV10.1 on cell proliferation
by p-38MAPK inhibition. Interestingly, modulation of KV10.1
expression levels by p-38MAPK pathway has been described
in MG-63 cells from osteosarcoma [102], so the relation
between the channel and p-38MAPK signalling needs further
clarification. Another non-conducting function of KV10.1 is
an increase in hypoxia resistance by boosting HIF-1 levels
and VEGF secretion, eventually leading to better tumour vas-
cularization [53]. Nevertheless, the mechanisms described
above remain insufficient to explain the benefit KV10.1
expression brings to the proliferation of so many different
cancer cell lines.
Finally, in some models, KV10.1 appears to be regulated
by cell cycle. Inducing the G2/M transition by progesterone
in Xenopus oocytes heterologously expressing KV10.1 causes
a reduction in current [17]. This reduction is dependent on
the mitosis-promoting factor (MPF, a complex of cyclin B
and p34cdc2) and obeys a voltage-dependent block by intra-
cellular Naþ [16]. MPF induces an increase in selectivity
during the M phase [120] that results in block by Naþ,
which leads to a rectification of the current–voltage relation.
The resulting net loss of Kþ conductance at G2/M transition
may be a way to achieve membrane depolarization associated
with mitosis. Cell-cycle regulation of KV10.1 has also been
studied in MCF-7 breast cancer cells. Synchronization of
these cells in G0/G1 by serum starvation leads to an increase
in Eag1 mRNA expression compared with unsynchronized
controls, with a further increase during the progression
through G1 and a decrease in the S-phase [121]. At the func-
tional level, this is accompanied by an increase in outward-
rectifier Kþ current that hyperpolarizes the membrane
towards the S-phase [121]. Both KV10.1 mRNA and KV10.1-
mediated current in MCF-7 cells can also be increased by
stimulation with insulin-like growth factor 1 (IGF-1) via
the PI3 K/Akt pathway, suggesting that the progression
through G1 to S triggered by IGF-1 can partially be owing
to its effect on KV10.1 [122]. Defective checkpoint control
between G1 and S-phase can also result in KV10.1 upregula-
tion. In SH-SY5Y neuroblastoma cells, KV10.1 expression is
regulated by the p53/mir34/E2F1 pathway [123]. Addition-
ally, keratinocytes immortalized with human papilloma
virus oncogenes E6 and E7 targeting p53 and Retinoblastoma
protein (pRb) start to transcribe KV10.1 mRNA [124]. One can
thus expect that p53 or pRb/E2F pathway inhibition or mal-
functions, which are very common in cancer, can give rise to
higher KV10.1 expression levels. However, further research is
rstb.
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Progression through the cell cycle is guarded by several
checkpoint control pathways that have the ability to delay or
stop further events, such as DNA synthesis or assembly of
the mitotic spindle, before commitment into cell division.
In accordance with the experimental data compiled in this
review, there can be little doubt that Kþ channels play an
active role in cell-cycle progression. On the other hand,
their expression or function can be regulated by the cell cycle.
Therefore, Kþ channels could also be viewed as effectors of
the checkpoint machinery. As molecular machines that
enable the passage of Kþ ions through the membrane, theycan regulate cell volume, provide driving force for Ca2þ
entry, hyperpolarize the cell at the G1/S transition and
depolarize it towards mitosis. Additionally, non-canonical,
permeation-independent mechanisms may be involved,
where Kþ channels recruit or modulate signalling cascades
via protein–protein interactions. It is tempting to assume that
signalling cascades activated by such interactions could link
the nuclear clock control with its cytoplasmic counterpart.
Unfortunately, to date we have only a rough estimate of
how membrane potential changes along the cell cycle. More-
over, very little is known about the non-conducting functions
of Kþ channels. Which signalling cascades can they modify?
How do they interact with other proteins? There are also
more general questions that remain unanswered. How exactly
does membrane potential affect the cell-cycle machinery?
Further research on Kþ channels in cell cycle and proliferation
will give us better understanding of these fundamental
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